Analyst Ratings for [SAGE] Sage Therapeutics, Inc.

3/11/25	Resumed	Underperform	X
SAGE SAGE Therapeutics BofA Securities
$5
11/21/24	Upgrades	Underperform Sec Perform	X
SAGE SAGE Therapeutics RBC Capital Mkts
$4
10/10/24	Resumed	Mkt Perform	X
SAGE SAGE Therapeutics Raymond James
10/4/24	Downgrades	Outperform Sec Perform	X
SAGE SAGE Therapeutics RBC Capital Mkts
$10 $4
7/30/24	Downgrades	Buy Hold	X
SAGE SAGE Therapeutics TD Cowen
$16 $10
7/25/24	Downgrades	Overweight Neutral	X
SAGE SAGE Therapeutics JP Morgan
$18 $12
5/29/24	Initiated	Sell	X
SAGE SAGE Therapeutics Citigroup
$8
5/29/24	Initiated	Neutral	X
SAGE SAGE Therapeutics Robert W. Baird
$15
4/17/24	Downgrades	Neutral Underperform	X
SAGE SAGE Therapeutics BofA Securities
$24 $14
12/12/23	Initiated	Hold	X
SAGE SAGE Therapeutics Deutsche Bank
$21
8/8/23	Downgrades	Buy Hold	X
SAGE SAGE Therapeutics Canaccord Genuity
$64 $21
8/8/23	Downgrades	Buy Neutral	X
SAGE SAGE Therapeutics Goldman
$22
8/8/23	Downgrades	Buy Hold	X
SAGE SAGE Therapeutics Needham
8/7/23	Downgrades	Buy Neutral	X
SAGE SAGE Therapeutics BofA Securities
$66 $25
8/7/23	Downgrades	Outperform Perform	X
SAGE SAGE Therapeutics Oppenheimer
8/7/23	Downgrades	Outperform Sec Perform	X
SAGE SAGE Therapeutics RBC Capital Mkts
$71 $25
8/7/23	Downgrades	Buy Hold	X
SAGE SAGE Therapeutics Stifel
$60 $22
8/7/23	Downgrades	Outperform Neutral	X
SAGE SAGE Therapeutics Wedbush
$51 $22
7/27/23	Initiated	Sector Outperform	X
SAGE SAGE Therapeutics Scotiabank
3/13/23	Upgrades	Sec Perform Outperform	X
SAGE SAGE Therapeutics RBC Capital Mkts
$40 $60
1/3/23	Downgrades	Buy Neutral	X
SAGE SAGE Therapeutics Guggenheim
11/1/22	Initiated	Hold	X
SAGE SAGE Therapeutics Loop Capital
$41
3/31/22	Initiated	Hold	X
SAGE SAGE Therapeutics Berenberg
$37
10/19/21	Resumed	Equal-Weight	X
SAGE SAGE Therapeutics Morgan Stanley
$78 $66
10/7/21	Downgrades	Buy Hold	X
SAGE SAGE Therapeutics Jefferies
$100 $50
6/16/21	Downgrades	Buy Neutral	X
SAGE SAGE Therapeutics Citigroup
$101 $68
4/7/21	Initiated	Overweight	X
SAGE SAGE Therapeutics Piper Sandler
$100
2/26/21	Downgrades	Buy Neutral	X
SAGE SAGE Therapeutics Mizuho
$81
2/25/21	Reiterated	Neutral	X
SAGE SAGE Therapeutics H.C. Wainwright
$74 $86
2/2/21	Resumed	Mkt Perform	X
SAGE SAGE Therapeutics Raymond James
1/22/21	Downgrades	Outperform Mkt Perform	X
SAGE SAGE Therapeutics BMO Capital Markets
$95
1/4/21	Upgrades	Neutral Buy	X
SAGE SAGE Therapeutics Guggenheim
1/4/21	Downgrades	Outperform Sec Perform	X
SAGE SAGE Therapeutics RBC Capital Mkts
$83 $86
5/23/19	Initiated	Outperform	X
SAGE SAGE Therapeutics Wedbush
4/25/19	Initiated	Buy	X
SAGE SAGE Therapeutics Jefferies
$195
12/14/18	Initiated	Outperform	X
SAGE SAGE Therapeutics Wolfe Research
10/11/18	Initiated	Outperform	X
SAGE SAGE Therapeutics Oppenheimer
$170
8/7/18	Reiterated	Buy	X
SAGE SAGE Therapeutics Stifel
$198 $239
8/6/18	Initiated	Overweight	X
SAGE SAGE Therapeutics Piper Jaffray
$206
6/6/18	Initiated	Buy	X
SAGE SAGE Therapeutics Ladenburg Thalmann
$230
3/26/18	Resumed	Buy	X
SAGE SAGE Therapeutics Canaccord Genuity
$210
2/26/18	Initiated	Overweight	X
SAGE SAGE Therapeutics Morgan Stanley

SAGE Sage Therapeutics, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.